Overview
Efficacy, Safety and Tolerability of XBD173 in Patients With Generalized Anxiety Disorder
Status:
Completed
Completed
Trial end date:
2006-05-01
2006-05-01
Target enrollment:
0
0
Participant gender:
All
All
Summary
This study will test the efficacy, safety and tolerability of XBD173 in the treatment of generalized anxiety disorder in patients.Phase:
Phase 2Accepts Healthy Volunteers?
NoDetails
Lead Sponsor:
Novartis Pharmaceuticals
Criteria
Inclusion Criteria:- Current doctor's diagnosis of generalized anxiety disorder
- In need of psychiatric treatment
- Willingness to complete all aspects of the study
Exclusion Criteria:
- Current doctor's diagnosis of major depression
- History of schizophrenia or schizoaffective disorders
- Drug dependence within 2 months prior to study start
For detailed information on eligibility, please contact the study center nearest to you
(see below), or call 1-862-778-8300, or visit the following website:
www.novartisclinicaltrials.com